Prosecution Insights
Last updated: April 19, 2026

Glaxosmithkline Intellectual Property Development Limited

8 pending office actions

Portfolio Summary

8
Total Pending OAs
2
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18613481 METHODS OF TREATING AN IL-5 MEDIATED DISEASE BY ADMINISTERING AN IL-5 BINDING PROTEIN HOWARD, ZACHARY C 1674 Non-Final OA Mar 22, 2024
18552477 ANTIGEN BINDING PROTEINS AND COMBINATIONS THEREOF LANDSMAN, ROBERT S 1647 Non-Final OA Sep 26, 2023
18256982 Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors SEITZ, ANTHONY JOSEPH 1629 Non-Final OA Jun 12, 2023
18042314 IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS AULAKH, CHARANJIT 1621 Non-Final OA Feb 21, 2023
17913072 ANTI-TN-MUC1 CHIMERIC ANTIGEN RECEPTORS HECK, BRYAN WILLIAM 1643 Non-Final OA Sep 20, 2022
17617479 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS ELENISTE, PIERRE PAUL 1622 Final Rejection Dec 08, 2021
17600660 GEPOTIDACIN FOR USE IN THE TREATMENT OF BACTERIAL URINARY TRACT INFECTIONS BRAUN, MADELINE E 1624 Non-Final OA Oct 01, 2021
17412070 NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES SCHMITT, MICHAEL J 1629 Final Rejection Aug 25, 2021

Managing Glaxosmithkline Intellectual Property Development Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month